212 related articles for article (PubMed ID: 18487070)
1. 2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.
Kawamoto A; Kodama E; Sarafianos SG; Sakagami Y; Kohgo S; Kitano K; Ashida N; Iwai Y; Hayakawa H; Nakata H; Mitsuya H; Arnold E; Matsuoka M
Int J Biochem Cell Biol; 2008; 40(11):2410-20. PubMed ID: 18487070
[TBL] [Abstract][Full Text] [Related]
2. The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase.
Takamatsu Y; Das D; Kohgo S; Hayashi H; Delino NS; Sarafianos SG; Mitsuya H; Maeda K
Cell Chem Biol; 2018 Oct; 25(10):1268-1278.e3. PubMed ID: 30174310
[TBL] [Abstract][Full Text] [Related]
3. Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Maeda K; Desai DV; Aoki M; Nakata H; Kodama EN; Mitsuya H
Antivir Ther; 2014; 19(2):179-89. PubMed ID: 24162098
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.
Michailidis E; Marchand B; Kodama EN; Singh K; Matsuoka M; Kirby KA; Ryan EM; Sawani AM; Nagy E; Ashida N; Mitsuya H; Parniak MA; Sarafianos SG
J Biol Chem; 2009 Dec; 284(51):35681-91. PubMed ID: 19837673
[TBL] [Abstract][Full Text] [Related]
5. M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.
Oliveira M; Brenner BG; Xu H; Ibanescu RI; Mesplède T; Wainberg MA
J Antimicrob Chemother; 2017 Nov; 72(11):3008-3011. PubMed ID: 28961903
[TBL] [Abstract][Full Text] [Related]
6. Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.
Michailidis E; Ryan EM; Hachiya A; Kirby KA; Marchand B; Leslie MD; Huber AD; Ong YT; Jackson JC; Singh K; Kodama EN; Mitsuya H; Parniak MA; Sarafianos SG
Retrovirology; 2013 Jun; 10():65. PubMed ID: 23800377
[TBL] [Abstract][Full Text] [Related]
7. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor.
Markowitz M; Sarafianos SG
Curr Opin HIV AIDS; 2018 Jul; 13(4):294-299. PubMed ID: 29697468
[TBL] [Abstract][Full Text] [Related]
8. Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.
Michailidis E; Singh K; Ryan EM; Hachiya A; Ong YT; Kirby KA; Marchand B; Kodama EN; Mitsuya H; Parniak MA; Sarafianos SG
Cell Mol Biol (Noisy-le-grand); 2012 Dec; 58(1):187-95. PubMed ID: 23273211
[TBL] [Abstract][Full Text] [Related]
9. Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.
Cilento ME; Reeve AB; Michailidis E; Ilina TV; Nagy E; Mitsuya H; Parniak MA; Tedbury PR; Sarafianos SG
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0116721. PubMed ID: 34516245
[TBL] [Abstract][Full Text] [Related]
10. Efficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdA.
Shanmugasundaram U; Kovarova M; Ho PT; Schramm N; Wahl A; Parniak MA; Garcia JV
PLoS One; 2016; 11(7):e0159517. PubMed ID: 27438728
[TBL] [Abstract][Full Text] [Related]
11. Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque.
Stoddart CA; Galkina SA; Joshi P; Kosikova G; Moreno ME; Rivera JM; Sloan B; Reeve AB; Sarafianos SG; Murphey-Corb M; Parniak MA
Antimicrob Agents Chemother; 2015 Jul; 59(7):4190-8. PubMed ID: 25941222
[TBL] [Abstract][Full Text] [Related]
12. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms.
Michailidis E; Huber AD; Ryan EM; Ong YT; Leslie MD; Matzek KB; Singh K; Marchand B; Hagedorn AN; Kirby KA; Rohan LC; Kodama EN; Mitsuya H; Parniak MA; Sarafianos SG
J Biol Chem; 2014 Aug; 289(35):24533-48. PubMed ID: 24970894
[TBL] [Abstract][Full Text] [Related]
13. Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kinetics.
Muftuoglu Y; Sohl CD; Mislak AC; Mitsuya H; Sarafianos SG; Anderson KS
Antiviral Res; 2014 Jun; 106():1-4. PubMed ID: 24632447
[TBL] [Abstract][Full Text] [Related]
14. The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase.
Kirby KA; Singh K; Michailidis E; Marchand B; Kodama EN; Ashida N; Mitsuya H; Parniak MA; Sarafianos SG
Cell Mol Biol (Noisy-le-grand); 2011 Feb; 57(1):40-6. PubMed ID: 21366961
[TBL] [Abstract][Full Text] [Related]
15. 4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.
Kodama EI; Kohgo S; Kitano K; Machida H; Gatanaga H; Shigeta S; Matsuoka M; Ohrui H; Mitsuya H
Antimicrob Agents Chemother; 2001 May; 45(5):1539-46. PubMed ID: 11302824
[TBL] [Abstract][Full Text] [Related]
16. MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.
Wu VH; Smith RA; Masoum S; Raugi DN; Ba S; Seydi M; Grobler JA; Gottlieb GS;
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559249
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes.
Njenda DT; Aralaguppe SG; Singh K; Rao R; Sönnerborg A; Sarafianos SG; Neogi U
J Antimicrob Chemother; 2018 Oct; 73(10):2721-2728. PubMed ID: 30053052
[TBL] [Abstract][Full Text] [Related]
18. Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice.
Hattori S; Ide K; Nakata H; Harada H; Suzu S; Ashida N; Kohgo S; Hayakawa H; Mitsuya H; Okada S
Antimicrob Agents Chemother; 2009 Sep; 53(9):3887-93. PubMed ID: 19546363
[TBL] [Abstract][Full Text] [Related]
19. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
Nakata H; Amano M; Koh Y; Kodama E; Yang G; Bailey CM; Kohgo S; Hayakawa H; Matsuoka M; Anderson KS; Cheng YC; Mitsuya H
Antimicrob Agents Chemother; 2007 Aug; 51(8):2701-8. PubMed ID: 17548498
[TBL] [Abstract][Full Text] [Related]
20. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.
Nitanda T; Wang X; Kumamoto H; Haraguchi K; Tanaka H; Cheng YC; Baba M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3355-60. PubMed ID: 16048947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
